title: Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms.
abstract: OBJECTIVE
  Tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors DR4 and DR5 have been mapped to chromosome 8p21-22, a region frequently deleted in different lymphoid neoplasms.
  
  
  METHODS
  To investigate the potential alterations of these genes in lymphoid neoplasms, we examined the presence of gene mutations in exons 3, 4, and 9 in 69 cases with mantle cell lymphoma (MCL), 16 with chronic lymphocytic leukemia (CLL), 12 with follicular lymphomas (FL) and 17 with large B-cell-lymphomas (DLBCL), as well as in 4 lymphoid cell lines carrying the t(11;14) translocation, and 91 healthy blood donors.
  
  
  RESULTS
  Three CLL and three MCL cases had 8p deletions. Two nucleotide changes in or near the intron 3 splice consensus sequence and a silent change were found. These rare changes were also present in the germ-line of the patients. The DR4 death domain A1322G polymorphism was significantly more frequent in MCL [odds ratio (OR) = 5.9; 95% confidence interval (CI), 1.92-18.1] and CLL (OR = 4.5; CI, 1.18-17) patients than in a sex and age-adjusted healthy population. In contrast, the DR4 exon 4 C626G polymorphism was associated with a significant overall decreased risk for MCL (OR = 0.3; CI, 0.12-0.8). No mutations or cancer-associated polymorphic changes were found in DR5 domains.
  
  
  CONCLUSIONS
  These findings indicate that mutations of DR4 and DR5 are uncommon in lymphoid neoplasms but DR4 polymorphic alleles may contribute to the pathogenesis of these malignancies.
authors.affiliation: Hematopathology Section, Laboratory of Pathology, Hematology Department, Hospital Clínic, Institut d'Investigacions Biomediques August Pi ISunyer, University of Barcelona, Barcelona, Spain.
authors.forename: Verònica
authors.initials: V
authors.lastname: Fernàndez
authors.forename: Pedro
authors.initials: P
authors.lastname: Jares
authors.forename: Sílvia
authors.initials: S
authors.lastname: Beà
authors.forename: Itziar
authors.initials: I
authors.lastname: Salaverria
authors.forename: Elisabet
authors.initials: E
authors.lastname: Guino
authors.forename: Sílvia
authors.initials: S
authors.lastname: de Sanjosé
authors.forename: Dolors
authors.initials: D
authors.lastname: Colomer
authors.forename: German
authors.initials: G
authors.lastname: Ott
authors.forename: Emili
authors.initials: E
authors.lastname: Montserrat
authors.forename: Elias
authors.initials: E
authors.lastname: Campo
mesh_terms: D000483:Alleles; D045744:Cell Line, Tumor; D004252:DNA Mutational Analysis; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D016393:Lymphoma, B-Cell / Q000235:genetics*; D020522:Lymphoma, Mantle-Cell / Q000235:genetics*; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor / Q000235:genetics*
chemical_list: D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand; D018124:Receptors, Tumor Necrosis Factor; C105190:TNFRSF10A protein, human; C505639:TNFRSF10B protein, human